Scientific Programme

Click here  to view or download the Final Programme

Thursday 11 April 2019

09.00   Registration Opens

11.00 – 11.10   Welcome Address
Christoph Zielinski, Vienna, Austria

11.10 – 11.30   Opening Lecture: Immunotherapy – next challenges of clinical drug development
Mario Sznol, New Haven, CT, USA

11.30 – 13.30 Plenary Symposium 1 – Microenvironment and metabolism
Chair: Mario Sznol, Christoph Zielinski

  • Imaging of T cell success and failure within the tumor microenvironment
    Emmanuel Donnadieu, Paris, France
  • Role of TGFß and CAFs in T cell exclusion”
    Eduard Batlle, Barcelona, Spain
  • Checkpoint inhibition and metabolic reprogramming
    Bo Huang, Beijing, China
  • Role of intratumoral memory T cells for immune surveillance
    Pedro Romero, Lausanne, Switzerland
  • Microbiota and its role for response to immunotherapy
    Lisa Derosa, Villejuif, France

13.30 – 14.30   Lunch

14.30 – 15.50   Plenary Symposium 2 – Emerging Concepts / New Agents
Chair: Samir Khleif, Pedro Romero

  • Targeting the CD73-adenosine axis for immunotherapy
    Paolo Ascierto, Naples Italy
  • Modulation of checkpoint antibodies
    Ana Anderson, Boston, MA, USA
  • Leukemic stem cells and immune evasion
    Claudia Lengerke, Basel, Switzerland
  • NK cells as target for therapeutic intervention
    Stéphanie Cornen, Marseille, France
  • The Siglec pathway – a target for improving T-cell activation
    Heinz Läubli, Basle, Switzerland

15.50 – 16.30   Coffee Break

16.30 – 18.30   Plenary Symposium 3 – Combination Therapy
Chair: Paolo Ascierto, Michael Bergmann

  • Rationales for combination strategies
    Samir Khleif, Augusta, GA, USA
  • Combination of checkpoint inhibition and vaccines
    Sjoerd van der Burg, Leiden, The Netherlands
  •  Interaction between cytokines and checkpoint inhibitors
    Aaron Ring, New Haven, CT, USA
  • Combination of Oncolytic Viruses and Checkpoint Inhibitors
    Alan Melcher, London, United Kingdom
  • Histon-Deacetylase inhibition in combination with immunotherapy
    Alfredo Budillon, Naples, Italy
  • O2 – Overall responses and survival in RCC on Pegilodecakin with anti-PD-1
    Aung Naing, Houston, TX, United States

18.30   Welcome Reception and Poster Viewing


Friday 12 April 2019

08.30 – 09.30   TNBC (Triple Negative Breast Cancer) Meet the Expert Session
Chair: Christoph Zielinski

  • Cancer immunotherapy/PD-L1 checkpoint inhibitors in Advanced Triple-Negative Breast Cancer
    Christoph Zielinski, Vienna, Austria
  • Predictive biomarkers for cancer immunotherapy in TNBC
    Luciana Molinero, San Francisco, CA, USA
  • Discussion

09.30 – 10.30   Plenary Symposium 4 – Preclinical Models
Chair: Eric Tartour, Lei Zheng

  • Tumor organoids and immune cells
    Emile Voest,  Amsterdam, The Netherlands
  • Analysis of the tumor microenvironment by single cell analysis
    Bernard Thienpont, Leuven, Belgium
  • In vivo imaging of immune responses using PET-CT
    Angela Krackhardt, Munich, Germany

10.30 – 11.00   Coffee Break

11.00 – 12.40   Plenary Symposium 5 – Precision Medicine Meets Immunotherapy
Chair: Heinz Zwierzina, Zihai Li

  • Challenges of including immunobiomarkers into clinical drug development
    Jeffrey Weber, New York, NY, USA
  • Circulating tumor DNA as a tool to predict response in immunotherapy
    François-Clément Bidard, Paris, France
  • T Cell subpopulations predict response to combination of PD-L1 blockage and chemotherapy
    Barbara Seliger, Halle, Germany
  • Prediction of efficacy and toxicity of immunotherapeutic agents
    Lei Zheng, Baltimore, MD, USA
  • System immunology and tumor microenvironment
    Jérôme Galon, Paris, France
  • O3 – A plasma-based assay for assessment of tumour mutational burden in patients with metastatic non-small cell lung cancer in the first-line treatment setting: results from the MYSTIC study
    Han Si, Gaithersburgh, MD, United States
  • O4 – Late-differentiated effector neoantigen-specific CD8+ T cells are enriched in non-small cell lung carcinoma patients responding to atezolizumab treatment
    Alessandra Nardin, Singapore, Singapore

12.45 – 13.15   Exhibitors (Pipeline) Session

Please click HERE to view details of the session

13.15 – 14.00   Lunch

 14.00 – 14.30   Poster Viewing with Presenters
Chair: Sebastian Kobold, Zihai Li, Volkmar Nüssler, Eric Tartour

14.30 – 15.15   Lifetime Achievement Award
Chair: Christoph Zielinski

  • Innate Immunity, Inflammation and Cancer: from bench to bedside
    Alberto Mantovani, Milan, Italy

15.15 – 15.45   Coffee Break

15.45 – 17.15   Plenary Symposium 6 – Cell Therapy
Chair: Lisa Butterfield, Michael von Bergwelt

  • Next generation cell therapies
    Lisa Butterfield, San Francisco, CA, United States
  • TRUCKs
    Hinrich Abken, Regensburg, Germany
  • Synthetic agonist receptor modified T cells: a new modular platform for T-cell therapy
    Sebastian Kobold, Munich, Germany
  • CAR-NK cell therapy
    Ulrike Koehl, Leipzig, Germany
  • O5 – Characterization of bispecific antibodies that drive synthetic agonistic receptor – transduced T Cells to mediate specific and conditional therapy in human pancreatic cancer models
    Mohamed-Reda Benmebarek, Munich, Germany

17.15 – 17.55   Plenary Session 7Young Researcher Session
Chair: Sebastian Kobold

  • O6 – A screening for novel immune-checkpoints identifies a serine/threonine kinase to confer Immune  resistance in multiple myeloma
    Valentina Volpin, Regensburg, Germany
  • O7 – Immune and mutational landscape in triple negative breast cancer and its evolution during neoadjuvant chemotherapy associated or not with GTN and anti-PD-1
    Nesrine Mabrouk, Dijon, France
  • O8 – In-situ diversification of immunity following vaccination targeting tumor neoepitopes; an integral component of combinatorial immunotherapy
    Karin Lee, Bethesda, MD, United States
  • O9 – Histone deacetylase inhibitors valproic acid and vorinostat enhance trastuzumab-mediated antibody-dependent cell-mediated phagocytosis
    Julijan Kabiljo, Vienna, Austria

19.30   ITOC6 Conference Dinner


Saturday 13 April 2019

08.30 – 09.30   Plenary Session 8Anticancer Vaccines
Chair: Cornelis Melief, Barbara Seliger

  • Challenges of anticancer vaccine development
    Cornelis Melief, Leiden, The Netherlands
  • Mimotopes  for Vaccination against Cancer
    Ursula Wiedermann-Schmidt, Vienna, Austria
  • Neoantigen vaccination
    David Reardon, Boston, MA, United States

09.30 – 11.10    Plenary Symposium 9 – Clinical Breakthrough with Immunotherapy – Part 1
Joint Session with ESMO
Chair: John Haanen, Paul Nathan

  • Immune related adverse events
    Michael von Bergwelt, Munich, Germany
  • Cell Therapy
    John Haanen, Amsterdam, The Netherlands
  • Checkpoint inhibition in hematological malignancies
    Dominik Wolf, Innsbruck, Austria
    Rudolf-Maria Huber, Munich, Germany
  • Melanoma
    Helen Gogas, Athens, Greece

11.10 – 11.40     Coffee Break

11.40 – 12.40     Plenary Symposium 9 – Clinical Breakthrough with Immunotherapy – Part 2
Joint Session with ESMO
Chair: Volkmar Nüssler, Michael von Bergwelt

  • Immunotherapy for GI Cancers – MSI and beyond
    Volker Heinemann, Munich, Germany
  • Renal Cancer
    Paul Nathan, London, United Kingdom
  • Head & Neck
    Marco Merlano, Cuneo, Italy

12.40 – 13.00   Best Poster Awards & Closing Remarks

13.00 – 14.00       Lunch